Retraction: Role of activated rac1/cdc42 in mediating endothelial cell proliferation and tumor angiogenesis in breast cancer (PLoS ONE (2013) 8: 6 (e66275) DOI: 10.1371/journal.pone.0066275);Role of Activated Rac1/Cdc42 in Mediating Endothelial Cell Proliferation and Tumor Angiogenesis in Breast Cancer

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Ma, Ji ^a,b   Xue, Yan ^a   Liu, Wenchao ^a   Yue, Caixia ^c   Bi, Feng ^c   Xu, Junqing ^a   Zhang, Jian ^d   Li, Yan ^d   Zhong, Cuiping ^b   Chen, Yan ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

^c SICHUAN UNIVERSITY   (China)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; PROTEIN CDC42; PROTEIN P53; RAC1 PROTEIN; VASCULOTROPIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CELL LEVEL; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN STABILITY; TUMOR VASCULARIZATION; UBIQUITINATION;

MUS MUSCULUS;

ANIMALS; BREAST NEOPLASMS; CDC42 GTP-BINDING PROTEIN; CELL PROLIFERATION; ENDOTHELIAL CELLS; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LEUPEPTINS; MCF-7 CELLS; MICE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN STABILITY; RAC1 GTP-BINDING PROTEIN; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878650360     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0240575     Document Type: Erratum

References (33)

1. Bergers G, Benjamin LE, (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3: 401-410.
2. Jain RK, Carmeliet P, (2012) SnapShot: Tumor angiogenesis. Cell 149: 1408-1408.e1.
3. Jubb AM, Harris AL, (2010) Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 11: 1172-1183.
4. Meng D, Mei A, Liu J, Kang X, Shi X, et al. (2012) NADPH Oxidase 4 Mediates Insulin-Stimulated HIF-1α and VEGF Expression, and Angiogenesis In Vitro. PLoS One 10: e48393.
5. Lichtenberger BM, Tan PK, Niederleithner H, Ferrara N, Petzelbauer P, et al. (2010) Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell 140: 268-279.
6. Grothey A, Galanis E, (2009) Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 6: 507-518.
7. Hoang MV, Whelan MC, Senger DR, (2004) Rho activity critically and selectively regulates endothelial cell organization during angiogenesis. Proc Natl Acad Sci U S A 101: 1874-1879.
8. Sawada N, Li Y, Liao JK, (2010) Novel aspects of the roles of Rac1 GTPase in the cardiovascular system. Curr Opin Pharmacol 10: 116-121.
9. Ma J, Xue Y, Cui W, Li Y, Zhao Q, et al. (2012) Ras homolog gene family, member A promotes p53 degradation and vascular endothelial growth factor-dependent angiogenesis through an interaction with murine double minute 2 under hypoxic conditions. Cancer 118: 4105-4116.
10. Ma J, Zhang J, Ma Y, Zheng J, Cheng Y, et al. (2012) Adenovirus-mediated RhoA shRNA suppresses growth of esophageal squamous cell carcinoma cells in vitro and in vivo. Med Oncol 29: 119-126.
11. Hoang MV, Nagy JA, Senger DR, (2011) Active Rac1 improves pathologic VEGF neovessel architecture and reduces vascular leak: mechanistic similarities with angiopoietin-1. Blood 117: 1751-1760.
12. Garrett TA, Van Buul JD, Burridge K, (2007) VEGF-induced Rac1 activation in endothelial cells is regulated by the guanine nucleotide exchange factor Vav2. Exp Cell Res 313: 3285-3297.
13. Bijman MN, van NAGP, Laurens N, van HVW, Boven E, (2006) Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton. Mol Cancer Ther 5: 2348-2357.
14. de Toledo M, Anguille C, Roger L, Roux P, Gadea G, (2012) Cooperative Anti-Invasive Effect of Cdc42/Rac1 Activation and ROCK Inhibition in SW620 Colorectal Cancer Cells with Elevated Blebbing Activity. PLoS One. 11: e48344.
15. Cascone I, Giraudo E, Caccavari F, Napione L, Bertotti E, et al. (2003) Temporal and spatial modulation of Rho GTPases during in vitro formation of capillary vascular network. Adherens junctions and myosin light chain as targets of Rac1 and RhoA. J Biol Chem 278: 50702-50713.
16. Xue Y, Bi F, Zhang X, Zhang S, Pan Y, et al. (2006) Role of Rac1 and Cdc42 in hypoxia induced p53 and von Hippel-Lindau suppression and HIF1alpha activation. Int J Cancer 118: 2965-72.
17. Zietz C, Rossle M, Haas C, Sendelhofert A, Hirschmann A, et al. (1998) MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am J Pathol 153: 1425-1433.
18. Pal S, Datta K, Mukhopadhyay D, (2001) Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res 61: 6952-6957.
19. Mukhopadhyay D, Knebelmann B, Cohen HT, Ananth S, Sukhatme VP, (1997) The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. Mol Cell Biol 17: 5629-5639.
20. Wu WJ, Tu S, Cerione RA, (2003) Activated Cdc42 sequesters c-Cbl and prevents EGF receptor degradation. Cell 114: 715-725.
21. Bond M, Wu YJ, Sala-Newby GB, Newby AC, (2008) Rho GTPase, Rac1, regulates Skp2 levels, vascular smooth muscle cell proliferation, and intima formation in vitro and in vivo. Cardiovasc Res 80: 290-298.
22. Zhao W, Wang YS, Hui YN, Zhu J, Zhang P, et al. (2008) Inhibition of proliferation, migration and tube formation of choroidal microvascular endothelial cells by targeting HIF-1alpha with short hairpin RNA-expressing plasmid DNA in human RPE cells in a coculture system. Graefes Archive for Clinical and Experimental Ophthalmology 246: 1413-1422.
23. Takata K, Morishige K, Takahashi T, Hashimoto K, Tsutsumi S, et al. (2008) Fasudil-induced hypoxia-inducible factor-1alpha degradation disrupts a hypoxia-driven vascular endothelial growth factor autocrine mechanism in endothelial cells. Mol Cancer Ther 7: 1551-1561.
24. Ang C, Guiot MC, Ramanakumar AV, Roberge D, Kavan P, (2010) Clinical significance of molecular biomarkers in glioblastoma. Can J Neurol Sci 37: 625-630.
25. Lee DC, Kang YK, Kim WH, Jang YJ, Kim DJ, et al. (2008) Functional and clinical evidence for NDRG2 as a candidate suppressor of liver cancer metastasis. Cancer Res 68: 4210-4220.
26. Viale G, Regan MM, Mastropasqua MG, Maffini F, Maiorano E, et al. (2008) Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 100: 207-212.
27. Yaziji H, Goldstein LC, Barry TS, Werling R, Hwang H, et al. (2004) HER-2 testing in breast cancer using parallel tissue-based methods. JAMA 291: 1972-1977.
28. Koh W, Mahan RD, Davis GE, (2008) Cdc42- and Rac1-mediated endothelial lumen formation requires Pak2, Pak4 and Par3, and PKC-dependent signaling. J Cell Sci 121: 989-1001.
29. Fiedler LR, (2009) Rac1 regulates cardiovascular development and postnatal function of endothelium. Cell Adh Migr 3: 143-145.
30. Spindler V, Schlegel N, Waschke J, (2010) Role of GTPases in control of microvascular permeability. Cardiovasc Res 87: 243-253.
31. Xue Y, Bi F, Zhang X, Pan Y, Liu N, et al. (2004) Inhibition of endothelial cell proliferation by targeting Rac1 GTPase with small interference RNA in tumor cells. Biochem Biophys Res Commun 320: 1309-1315.
32. Fritz G, Brachetti C, Bahlmann F, Schmidt M, Kaina B, (2002) Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer 87: 635-644.
33. Su LF, Knoblauch R, Garabedian MJ, (2001) Rho GTPases as modulators of the estrogen receptor transcriptional response. J Biol Chem 276: 3231-7.